CD86 and colorectal carcinoma: mIF-based quantitative analysis revealed significantly higher counts of CD68+CD163+ and CD68+CD86+ TAMs and an elevated CD68+CD163+/CD68+CD86+ TAMs ratio in the CRC cohort (n=6) compared to the CAS cohort (n=10) and normal controls(n=4).